Grant Private Wealth Management Inc Takes Position in Johnson & Johnson (NYSE:JNJ)

Grant Private Wealth Management Inc purchased a new stake in Johnson & Johnson (NYSE:JNJ) in the 4th quarter, Holdings Channel.com reports. The institutional investor purchased 2,113 shares of the company’s stock, valued at approximately $306,000.

Several other large investors have also recently added to or reduced their stakes in the company. Principal Financial Group Inc. raised its position in shares of Johnson & Johnson by 10.5% in the third quarter. Principal Financial Group Inc. now owns 3,472,312 shares of the company’s stock valued at $562,723,000 after buying an additional 329,473 shares in the last quarter. United Bank raised its holdings in Johnson & Johnson by 5.6% in the 3rd quarter. United Bank now owns 3,788 shares of the company’s stock valued at $614,000 after acquiring an additional 202 shares in the last quarter. Resurgent Financial Advisors LLC lifted its position in shares of Johnson & Johnson by 10.1% during the 3rd quarter. Resurgent Financial Advisors LLC now owns 13,297 shares of the company’s stock valued at $2,155,000 after acquiring an additional 1,217 shares during the period. Royal London Asset Management Ltd. grew its holdings in shares of Johnson & Johnson by 2.0% during the 3rd quarter. Royal London Asset Management Ltd. now owns 1,626,795 shares of the company’s stock worth $263,638,000 after purchasing an additional 31,334 shares in the last quarter. Finally, Quantinno Capital Management LP increased its position in shares of Johnson & Johnson by 29.0% in the third quarter. Quantinno Capital Management LP now owns 219,599 shares of the company’s stock worth $35,588,000 after purchasing an additional 49,307 shares during the period. Institutional investors own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

JNJ has been the topic of a number of analyst reports. Royal Bank of Canada reiterated an “outperform” rating and set a $181.00 price objective on shares of Johnson & Johnson in a research note on Wednesday. Raymond James decreased their price objective on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a research note on Thursday, January 23rd. Leerink Partners cut their target price on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a research note on Thursday, January 23rd. Guggenheim reiterated a “neutral” rating on shares of Johnson & Johnson in a research note on Wednesday. Finally, Stifel Nicolaus dropped their price objective on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a research report on Thursday, January 23rd. Nine investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $171.33.

Johnson & Johnson Price Performance

JNJ stock opened at $155.41 on Thursday. The company has a market capitalization of $374.51 billion, a P/E ratio of 23.37, a PEG ratio of 2.56 and a beta of 0.47. The company has a fifty day moving average price of $159.36 and a 200-day moving average price of $155.98. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.99 by $0.05. The business had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. Johnson & Johnson’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same period last year, the company earned $2.29 EPS. As a group, equities analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Timothy Schmid sold 403 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the sale, the executive vice president now directly owns 15,098 shares in the company, valued at approximately $2,357,552.70. The trade was a 2.60 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Robert J. Decker sold 6,999 shares of the business’s stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the transaction, the vice president now owns 21,001 shares in the company, valued at $3,483,645.88. The trade was a 25.00 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is owned by insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.